Articles from Zealand Pharma

Zealand Pharma increases its share capital as a result of the exercise of employee warrants

Company announcement – No. 20 / 2025

By Zealand Pharma · Via GlobeNewswire · September 11, 2025

SAVE THE DATE: Zealand Pharma to host Capital Markets Day in London on December 11, 2025

Press release – No.13 / 2025

By Zealand Pharma · Via GlobeNewswire · September 11, 2025

Zealand Pharma to participate in upcoming investor conferences in September 2025

Press release – No. 12 / 2025

By Zealand Pharma · Via GlobeNewswire · August 28, 2025

Zealand Pharma major shareholder announcement: Van Herk Investments B.V.

Company announcement – No. 19 / 2025

By Zealand Pharma · Via GlobeNewswire · August 20, 2025

Zealand Pharma Announces Financial Results for the First Half of 2025

Company announcement – No. 18 / 2025

By Zealand Pharma · Via GlobeNewswire · August 14, 2025

Zealand Pharma conference call on August 14 at 2pm CET (8am ET) to present second quarter 2025 financial results

Press Release – No. 11 / 2025

By Zealand Pharma · Via GlobeNewswire · August 7, 2025

Zealand Pharma major shareholder announcement: Van Herk Investments B.V.

Company announcement – No. 17 / 2025

By Zealand Pharma · Via GlobeNewswire · July 18, 2025

Total number of shares and voting rights in Zealand Pharma as of June 30, 2025

Company announcement – No. 16 / 2025

By Zealand Pharma · Via GlobeNewswire · June 30, 2025

Zealand Pharma announces positive topline results from 28-week Phase 1b trial with GLP-1/GLP-2 receptor dual agonist dapiglutide

Company announcement – No. 15 / 2025

By Zealand Pharma · Via GlobeNewswire · June 18, 2025

Zealand Pharma increases its share capital as a result of the exercise of employee warrants

Company announcement – No. 14 / 2025

By Zealand Pharma · Via GlobeNewswire · June 6, 2025

Zealand Pharma submits Marketing Authorization Application to the European Medicines Agency for glepaglutide in short bowel syndrome

Press release – No. 10 / 2025

By Zealand Pharma · Via GlobeNewswire · June 2, 2025

Transactions in Zealand Pharma shares and/or related securities by persons discharging managerial responsibilities and/or their closely associated persons

Company announcement – No. 13 / 2025

By Zealand Pharma · Via GlobeNewswire · May 27, 2025

Zealand Pharma continues to strengthen strategic leadership of innovation in obesity and related conditions with appointment of Steven Johnson as Chief Development Officer

Press release – No. 9 / 2025

By Zealand Pharma · Via GlobeNewswire · May 19, 2025

Zealand Pharma to participate in upcoming healthcare investor conferences in May and June 2025

Press release – No. 8 / 2025

By Zealand Pharma · Via GlobeNewswire · May 12, 2025

Zealand Pharma announces closing of collaboration and license agreement with Roche

Company announcement – No. 12 / 2025

By Zealand Pharma · Via GlobeNewswire · May 9, 2025

Zealand Pharma Announces Financial Results for the First Three Months of 2025

Company announcement – No. 11 / 2025

By Zealand Pharma · Via GlobeNewswire · May 8, 2025

Zealand Pharma conference call on May 8 at 2pm CET (8am ET) to present first quarter 2025 financial results

Press Release – No. 7 / 2025

By Zealand Pharma · Via GlobeNewswire · May 1, 2025

Zealand Pharma announces first participant enrolled in Phase 2b ZUPREME-2 trial of petrelintide in people with overweight or obesity and type 2 diabetes

Press release – No. 6 / 2025

By Zealand Pharma · Via GlobeNewswire · April 24, 2025

Zealand Pharma appoints Utpal Singh as Chief Scientific Officer to drive next-generation peptide therapeutics discovery

Press release – No. 5 / 2025

By Zealand Pharma · Via GlobeNewswire · April 23, 2025

Transactions in Zealand Pharma shares and/or related securities by persons discharging managerial responsibilities and/or their closely associated persons

Company announcement – No. 10 / 2025

By Zealand Pharma · Via GlobeNewswire · April 19, 2025

Zealand Pharma launches long-term incentive programs for Zealand Pharma’s Board of Directors, Corporate Management and employees for 2025

Company announcement – No. 9 / 2025

By Zealand Pharma · Via GlobeNewswire · April 19, 2025

Total number of shares and voting rights in Zealand Pharma as of March 31, 2025

Company announcement – No. 8 / 2025

By Zealand Pharma · Via GlobeNewswire · March 31, 2025

Zealand Pharma major shareholder announcement: Van Herk Investments B.V.

Company announcement – No. 6 / 2025

By Zealand Pharma · Via GlobeNewswire · March 25, 2025

Zealand Pharma increases its share capital as a result of the exercise of employee warrants

Company announcement – No. 5 / 2025

By Zealand Pharma · Via GlobeNewswire · March 20, 2025

Zealand Pharma announces completion of enrollment in the Phase 2b ZUPREME-1 trial of petrelintide in people with overweight or obesity

Press release – No. 4 / 2025

By Zealand Pharma · Via GlobeNewswire · March 17, 2025

Zealand Pharma and Roche enter collaboration and license agreement to co-develop and co-commercialize petrelintide as a future foundational therapy for people with overweight and obesity

Company announcement – No. 4 / 2025

By Zealand Pharma · Via GlobeNewswire · March 12, 2025

Zealand Pharma Announces Financial Results for the Full Year 2024

Company announcement – No. 2 / 2025

By Zealand Pharma · Via GlobeNewswire · February 20, 2025

Zealand Pharma conference call on February 20 at 2pm CET (8am ET) to present full year 2024 financial results

Press Release – No. 3 / 2025

By Zealand Pharma · Via GlobeNewswire · February 13, 2025

Steven R. Smith, MD, joins Zealand Pharma as Senior Global Medical Advisor in Obesity

Press Release – No. 2 / 2025

By Zealand Pharma · Via GlobeNewswire · January 7, 2025

Zealand Pharma to present at the 43rd Annual J.P. Morgan Healthcare Conference on January 13th

Press Release – No. 1 / 2025

By Zealand Pharma · Via GlobeNewswire · January 6, 2025

U.S. Food and Drug Administration issues Complete Response Letter for the glepaglutide New Drug Application for the treatment of short bowel syndrome

Company announcement – No. 51 / 2024

By Zealand Pharma · Via GlobeNewswire · December 19, 2024

Zealand Pharma announces first participant enrolled in Phase 2b ZUPREME-1 trial of petrelintide in people with overweight or obesity

Press Release – No. 12 / 2024

By Zealand Pharma · Via GlobeNewswire · December 10, 2024

Zealand Pharma to participate in the Jefferies London Healthcare Conference

Press Release – No. 11 / 2024

By Zealand Pharma · Via GlobeNewswire · November 13, 2024

Zealand Pharma Announces Financial Results for the First Nine Months of 2024

Company announcement – No. 49 / 2024

By Zealand Pharma · Via GlobeNewswire · November 7, 2024

Zealand Pharma conference call on November 7 at 2pm CET (8am ET) to present third quarter 2024 financial results

Press Release – No. 10 / 2024

By Zealand Pharma · Via GlobeNewswire · November 1, 2024

Zealand Pharma provides U.S. regulatory update on dasiglucagon in congenital hyperinsulinism

Company announcement – No. 48 / 2024

By Zealand Pharma · Via GlobeNewswire · October 8, 2024

Zealand Pharma announces that Boehringer receives U.S. FDA Breakthrough Therapy designation and initiates two Phase III trials in MASH for survodutide

Company announcement – No. 47 / 2024

By Zealand Pharma · Via GlobeNewswire · October 8, 2024

Total number of shares and voting rights in Zealand Pharma A/S on September 30, 2024

Company announcement – No. 46 / 2024

By Zealand Pharma · Via GlobeNewswire · September 30, 2024

Zealand Pharma to participate in the 2024 Cantor Global Healthcare Conference on September 18th

Press Release – No. 9 / 2024

By Zealand Pharma · Via GlobeNewswire · September 13, 2024

Zealand Pharma Increases its Share Capital as a Consequence of Exercise of Employee Warrants

Company announcement – No. 45 / 2024

By Zealand Pharma · Via GlobeNewswire · September 12, 2024

Zealand Pharma announces positive topline results from 13-week Phase 1b multiple ascending dose clinical trial with GLP-1/GLP-2 receptor dual agonist dapiglutide

Company announcement – No. 44 / 2024

By Zealand Pharma · Via GlobeNewswire · September 9, 2024

Zealand Pharma Increases its Share Capital as a Consequence of Exercise of Employee Warrants

Company announcement – No. 41 / 2024

By Zealand Pharma · Via GlobeNewswire · August 22, 2024

Zealand Pharma Announces Financial Results for the First Half of 2024

Company announcement - No. 39 / 2024

By Zealand Pharma · Via GlobeNewswire · August 15, 2024

Zealand Pharma conference call on August 15 at 2pm CET (8am ET) to present first half 2024 financial results

Press Release – No. 8 / 2024

By Zealand Pharma · Via GlobeNewswire · August 12, 2024

Zealand Pharma Appoints Eric Cox as Chief Commercial Officer

Press release – 7 / 2024

By Zealand Pharma · Via GlobeNewswire · July 29, 2024

Zealand Pharma announces completion of an upsized equity offering of 8.35 million new ordinary shares raising gross proceeds of USD 1 billion / DKK 7 billion

Company announcement – No. 35 / 2024

By Zealand Pharma · Via GlobeNewswire · June 25, 2024

Zealand Pharma announces upsizing of previously announced equity offering from approximately USD 900 million / DKK 6.257 billion to USD 1 billion / DKK 7 billion

Company announcement – No. 34 / 2024

By Zealand Pharma · Via GlobeNewswire · June 25, 2024

Zealand Pharma launches equity offering of new shares raising gross proceeds of approximately USD 900 million / DKK 6.257 billion

Company announcement – No. 33 / 2024

By Zealand Pharma · Via GlobeNewswire · June 25, 2024

Zealand Pharma announces positive topline results from the Phase 1b 16-week multiple ascending dose clinical trial with long-acting amylin analog petrelintide

Company announcement – No. 32 / 2024

By Zealand Pharma · Via GlobeNewswire · June 20, 2024

Zealand Pharma announces that Boehringer Ingelheim’s survodutide demonstrates breakthrough improvement in liver fibrosis with no worsening of MASH in 64.5% of patients with F2 and F3 fibrosis

Company announcement - No. 30 / 2024

By Zealand Pharma · Via GlobeNewswire · June 7, 2024

Zealand Pharma announces that Boehringer Ingelheim will present positive results from Phase 2 trial with survodutide in MASH at EASL

Company announcement - No. 29 / 2024

By Zealand Pharma · Via GlobeNewswire · June 6, 2024

Zealand Pharma announces positive CHMP opinion for dasiglucagon for treatment of severe hypoglycemia in diabetes from European Medicines Agency

Press release – No. 6 / 2024

By Zealand Pharma · Via GlobeNewswire · May 31, 2024

Zealand Pharma to participate in upcoming healthcare investor conferences in June 2024

Press release – No. 5 / 2024

By Zealand Pharma · Via GlobeNewswire · May 29, 2024

Zealand Pharma announces topline results from the mechanistic investigator-led DREAM trial with low doses of GLP-1/GLP-2 receptor dual agonist dapiglutide

Company announcement – No. 27 / 2024

By Zealand Pharma · Via GlobeNewswire · May 23, 2024

Zealand Pharma Announces Financial Results for the First Quarter of 2024

Company announcement - No. 26 / 2024

By Zealand Pharma · Via GlobeNewswire · May 16, 2024

Zealand Pharma conference call on May 16 at 2pm CET (8am ET) to present first quarter 2024 financial results

Press Release – No. 4 / 2024

By Zealand Pharma · Via GlobeNewswire · May 9, 2024

Zealand Pharma to Participate in TD Cowen’s 44th Annual Health Care Conference

Press release – No. 3 / 2023

By Zealand Pharma · Via GlobeNewswire · March 1, 2024

Zealand Pharma Announces Financial Results for the Full Year 2023

Company announcement - No. 9 / 2024

By Zealand Pharma · Via GlobeNewswire · February 27, 2024

Zealand Pharma announces Boehringer Ingelheim survodutide Phase 2 trial shows 83% of adults treated achieved groundbreaking results in liver disease due to MASH, with significant improvements in fibrosis

Company announcement - No. 8 / 2024

By Zealand Pharma · Via GlobeNewswire · February 26, 2024

Zealand Pharma conference call on February 27 at 2pm CET (8am ET) to present full year 2023 financial results

Press Release – No. 2 / 2024

By Zealand Pharma · Via GlobeNewswire · February 20, 2024

Zealand Pharma major shareholder announcement: J O Hambro Capital Management

Company announcement – No. 5 / 2024

By Zealand Pharma · Via GlobeNewswire · January 19, 2024

Zealand Pharma major shareholder announcement: J O Hambro Capital Management

Company announcement – No. 4 / 2024

By Zealand Pharma · Via GlobeNewswire · January 17, 2024

Zealand Pharma completes registration of capital increase

Company announcement – No. 3 / 2024

By Zealand Pharma · Via GlobeNewswire · January 12, 2024

Zealand Pharma major shareholder announcement: Avoro Capital Advisors LLC

Company announcement – No. 2 / 2024

By Zealand Pharma · Via GlobeNewswire · January 10, 2024

Zealand Pharma announces directed issue and private placement for gross proceeds of DKK 1.45 billion

Company announcement – No. 1 / 2024

By Zealand Pharma · Via GlobeNewswire · January 8, 2024

Zealand Pharma to participate in the Goldman Sachs Healthcare C-Suite Unscripted Conference on January 4th

Press Release – No. 1 / 2024

By Zealand Pharma · Via GlobeNewswire · January 2, 2024

U.S. Food and Drug Administration issues Complete Response Letter for dasiglucagon in congenital hyperinsulinism for up to three weeks of dosing due to inspection findings at third-party manufacturing facility

Company announcement – No. 45 / 2023

By Zealand Pharma · Via GlobeNewswire · December 23, 2023

Zealand Pharma submits New Drug Application to the US FDA for glepaglutide in short bowel syndrome

Press release – No. 18 / 2023

By Zealand Pharma · Via GlobeNewswire · December 22, 2023

Zealand Pharma enters into EUR 90 million finance agreement with the European Investment Bank

Press release No. 17 / 2023

By Zealand Pharma · Via GlobeNewswire · December 22, 2023

Zealand Pharma to highlight obesity pipeline at R&D Event on December 5

Press release – No. 16 / 2023

By Zealand Pharma · Via GlobeNewswire · December 4, 2023

Zealand Pharma appoints Enrique Conterno and Elaine Sullivan as board observers

Company announcement – No. 40 / 2023

By Zealand Pharma · Via GlobeNewswire · November 30, 2023

Zealand Pharma Announces Financial Results for the First Nine Months of 2023

Company announcement - No. 38 / 2023

By Zealand Pharma · Via GlobeNewswire · November 9, 2023

Zealand Pharma to participate in the Jefferies London Healthcare Conference in November 2023

Press release – No. 15 / 2023

By Zealand Pharma · Via GlobeNewswire · November 7, 2023

Zealand Pharma conference call on November 9 at 2pm CET (8am ET) to present third quarter 2023 results

Press Release – No. 14 / 2023

By Zealand Pharma · Via GlobeNewswire · November 3, 2023

Zealand Pharma presents data for amylin analog ZP8396 at ObesityWeek

Press release – No. 13 / 2023

By Zealand Pharma · Via GlobeNewswire · October 17, 2023